Manufacturing Partners As a seed-stage biotech developing an extracorporeal CO2 removal device with a small team, Cor Therapeutics is likely to need GMP-capable contract manufacturers, sterile assembly, biocompatible materials, QA/regulatory-compliant suppliers, and an efficient supply chain to scale production; initiate outreach to CMOs with cardiovascular or critical care device experience to explore early manufacturing partnerships.

Regulatory & Trials With ongoing clinical development for a novel CO2 device, the company can benefit from early engagement with medical device regulatory consultants and CROs to design phase-focused trials, navigate PMA or 510(k) paths, and prepare regulatory filings and risk management plans.

Hospital Adoption Target hospital systems and critical care networks where hypercarbic respiratory failure is managed; identify key opinion leaders in pulmonology and intensive care, propose pilot programs or early-access studies, and map reimbursement pathways to support device adoption.

Strategic Investment Leverage the SF Bay Area biotech ecosystem and a prior seed round to attract strategic investors or corporate partners for co development, distribution, or manufacturing scale, especially from firms focused on respiratory or extracorporeal therapies.

Product Synergy Highlight the companys work on a novel filtration system alongside the CO2 removal device to pursue cross-vertical partnerships with dialysis and critical care device manufacturers, expanding potential OEM and collaboration opportunities.